FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067945145> ?p ?o ?g. }

• W2067945145 endingPage "320" @default.
• W2067945145 startingPage "313" @default.
• W2067945145 abstract "Objective To assess the efficacy and tolerability of mirabegron 25 mg and 50 mg once-daily vs placebo in patients with overactive bladder (OAB). Materials and Methods Patients ≥18 years with OAB symptoms were recruited to a 2-week, single-blind, placebo run-in. Those with ≥8 micturitions per 24 hours and ≥3 urgency episodes were randomized 1:1:1 to once-daily mirabegron 25 mg or 50 mg, or placebo for 12 weeks. Primary endpoints were changes to final visit in mean number of incontinence episodes and micturitions per 24 hours. Key secondary endpoints were changes to final visit in mean volume voided or micturition, change to week 4 in mean number of incontinence episodes and micturitions per 24 hours, changes to final visit in mean level of urgency, number of urgency incontinence episodes, and urgency (grade 3 or 4) episodes per 24 hours. Patient-reported outcomes were assessed using the OAB-questionnaire, Patient Perception of Bladder Condition, and Treatment-Satisfaction-Visual Analog Scale. Results Both mirabegron groups demonstrated statistically significant improvements in coprimary endpoints vs placebo. Mirabegron 50 mg demonstrated significantly greater improvements vs placebo in the following: change to final visit in mean volume voided per micturition and change to week 4 in mean number of incontinence episodes per 24 hours. Statistically significant improvements vs placebo were demonstrated by mirabegron 50 mg in all patient-reported outcome scales with no increase in the incidence of treatment-emergent adverse events vs placebo. Conclusion Mirabegron 25 mg and 50 mg were associated with significant improvements in efficacy measures of incontinence episodes and micturition frequency. Mirabegron was well tolerated vs placebo. To assess the efficacy and tolerability of mirabegron 25 mg and 50 mg once-daily vs placebo in patients with overactive bladder (OAB). Patients ≥18 years with OAB symptoms were recruited to a 2-week, single-blind, placebo run-in. Those with ≥8 micturitions per 24 hours and ≥3 urgency episodes were randomized 1:1:1 to once-daily mirabegron 25 mg or 50 mg, or placebo for 12 weeks. Primary endpoints were changes to final visit in mean number of incontinence episodes and micturitions per 24 hours. Key secondary endpoints were changes to final visit in mean volume voided or micturition, change to week 4 in mean number of incontinence episodes and micturitions per 24 hours, changes to final visit in mean level of urgency, number of urgency incontinence episodes, and urgency (grade 3 or 4) episodes per 24 hours. Patient-reported outcomes were assessed using the OAB-questionnaire, Patient Perception of Bladder Condition, and Treatment-Satisfaction-Visual Analog Scale. Both mirabegron groups demonstrated statistically significant improvements in coprimary endpoints vs placebo. Mirabegron 50 mg demonstrated significantly greater improvements vs placebo in the following: change to final visit in mean volume voided per micturition and change to week 4 in mean number of incontinence episodes per 24 hours. Statistically significant improvements vs placebo were demonstrated by mirabegron 50 mg in all patient-reported outcome scales with no increase in the incidence of treatment-emergent adverse events vs placebo. Mirabegron 25 mg and 50 mg were associated with significant improvements in efficacy measures of incontinence episodes and micturition frequency. Mirabegron was well tolerated vs placebo." @default.
• W2067945145 created "2016-06-24" @default.
• W2067945145 creator A5002038596 @default.
• W2067945145 creator A5017757704 @default.
• W2067945145 creator A5027536929 @default.
• W2067945145 creator A5030026004 @default.
• W2067945145 creator A5037409905 @default.
• W2067945145 creator A5044358928 @default.
• W2067945145 creator A5073537684 @default.
• W2067945145 creator A5086171372 @default.
• W2067945145 creator A5089190863 @default.
• W2067945145 creator A5091477558 @default.
• W2067945145 date "2013-08-01" @default.
• W2067945145 modified "2023-10-04" @default.
• W2067945145 title "A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder" @default.
• W2067945145 cites W1585489386 @default.
• W2067945145 cites W1972477468 @default.
• W2067945145 cites W1974084711 @default.
• W2067945145 cites W1976101513 @default.
• W2067945145 cites W1976724310 @default.
• W2067945145 cites W1996242258 @default.
• W2067945145 cites W2024813481 @default.
• W2067945145 cites W2033133691 @default.
• W2067945145 cites W2082897746 @default.
• W2067945145 cites W2084883802 @default.
• W2067945145 cites W2088679190 @default.
• W2067945145 cites W2092749677 @default.
• W2067945145 cites W2107806473 @default.
• W2067945145 cites W2133603145 @default.
• W2067945145 cites W2153390278 @default.
• W2067945145 cites W2169016904 @default.
• W2067945145 doi "https://doi.org/10.1016/j.urology.2013.02.077" @default.
• W2067945145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23769122" @default.
• W2067945145 hasPublicationYear "2013" @default.
• W2067945145 type Work @default.
• W2067945145 sameAs 2067945145 @default.
• W2067945145 citedByCount "203" @default.
• W2067945145 countsByYear W20679451452013 @default.
• W2067945145 countsByYear W20679451452014 @default.
• W2067945145 countsByYear W20679451452015 @default.
• W2067945145 countsByYear W20679451452016 @default.
• W2067945145 countsByYear W20679451452017 @default.
• W2067945145 countsByYear W20679451452018 @default.
• W2067945145 countsByYear W20679451452019 @default.
• W2067945145 countsByYear W20679451452020 @default.
• W2067945145 countsByYear W20679451452021 @default.
• W2067945145 countsByYear W20679451452022 @default.
• W2067945145 countsByYear W20679451452023 @default.
• W2067945145 crossrefType "journal-article" @default.
• W2067945145 hasAuthorship W2067945145A5002038596 @default.
• W2067945145 hasAuthorship W2067945145A5017757704 @default.
• W2067945145 hasAuthorship W2067945145A5027536929 @default.
• W2067945145 hasAuthorship W2067945145A5030026004 @default.
• W2067945145 hasAuthorship W2067945145A5037409905 @default.
• W2067945145 hasAuthorship W2067945145A5044358928 @default.
• W2067945145 hasAuthorship W2067945145A5073537684 @default.
• W2067945145 hasAuthorship W2067945145A5086171372 @default.
• W2067945145 hasAuthorship W2067945145A5089190863 @default.
• W2067945145 hasAuthorship W2067945145A5091477558 @default.
• W2067945145 hasConcept C126322002 @default.
• W2067945145 hasConcept C126894567 @default.
• W2067945145 hasConcept C142724271 @default.
• W2067945145 hasConcept C168563851 @default.
• W2067945145 hasConcept C175768497 @default.
• W2067945145 hasConcept C197934379 @default.
• W2067945145 hasConcept C203092338 @default.
• W2067945145 hasConcept C204787440 @default.
• W2067945145 hasConcept C27081682 @default.
• W2067945145 hasConcept C2778164427 @default.
• W2067945145 hasConcept C2778375690 @default.
• W2067945145 hasConcept C2778531004 @default.
• W2067945145 hasConcept C2778941218 @default.
• W2067945145 hasConcept C42219234 @default.
• W2067945145 hasConcept C71924100 @default.
• W2067945145 hasConcept C77411442 @default.
• W2067945145 hasConceptScore W2067945145C126322002 @default.
• W2067945145 hasConceptScore W2067945145C126894567 @default.
• W2067945145 hasConceptScore W2067945145C142724271 @default.
• W2067945145 hasConceptScore W2067945145C168563851 @default.
• W2067945145 hasConceptScore W2067945145C175768497 @default.
• W2067945145 hasConceptScore W2067945145C197934379 @default.
• W2067945145 hasConceptScore W2067945145C203092338 @default.
• W2067945145 hasConceptScore W2067945145C204787440 @default.
• W2067945145 hasConceptScore W2067945145C27081682 @default.
• W2067945145 hasConceptScore W2067945145C2778164427 @default.
• W2067945145 hasConceptScore W2067945145C2778375690 @default.
• W2067945145 hasConceptScore W2067945145C2778531004 @default.
• W2067945145 hasConceptScore W2067945145C2778941218 @default.
• W2067945145 hasConceptScore W2067945145C42219234 @default.
• W2067945145 hasConceptScore W2067945145C71924100 @default.
• W2067945145 hasConceptScore W2067945145C77411442 @default.
• W2067945145 hasIssue "2" @default.
• W2067945145 hasLocation W20679451451 @default.
• W2067945145 hasLocation W20679451452 @default.
• W2067945145 hasOpenAccess W2067945145 @default.
• W2067945145 hasPrimaryLocation W20679451451 @default.
• W2067945145 hasRelatedWork W1787320721 @default.
• W2067945145 hasRelatedWork W2071699168 @default.

• next